Patents by Inventor James Barnaby
James Barnaby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041212Abstract: A chair comprises a seat pan member, a seat back member having a lumbar support member, a lumbar support assembly operatively connected to the lumbar support member and configured for moving the lumbar support member, with respect to the seat pan member and the seat back member, between at least a first position and a second position, and an actuator configured to operate the lumbar support assembly for movement of the lumbar support member between at least the first position and the second position. When the lumbar support member is in the second position, the lumbar support member is positioned forwardly, in a direction toward the seated user's lower back, relative to the seat back member so as to enable the user to be seated forwardly on the seat pan member while being engaged with the lumbar support member.Type: ApplicationFiled: October 17, 2023Publication date: February 8, 2024Inventors: Tai Hoon K. MATLIN, James WARING, Shawn APPLEGATE, Steven James BARNABY, JR., Peter MALETICH, John FELLOWES
-
Publication number: 20230390392Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a combination of genes and their corresponding proteins. In several embodiments, one edit is to reduce expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR and at least two additional gene edits to enhance the cytotoxicity and/or persistence of the resulting cells. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.Type: ApplicationFiled: March 6, 2023Publication date: December 7, 2023Inventors: James Barnaby Trager, Ivan Chan, Chao Guo, Luxuan Guo Buren, Alexandra Leida Liana Lazetic, Mary-Lee Dequéant, Hanspeter Waldner, Changan Guo, Chandirasegaran Massilamany, Ming-Hong Xie, Elizabeth N. Koch, Jacob Usadi, Parin Sripakdeevong
-
Patent number: 11819137Abstract: A chair comprises a seat pan member, a seat back member having a lumbar support member, a lumbar support assembly operatively connected to the lumbar support member and configured for moving the lumbar support member, with respect to the seat pan member and the seat back member, between at least a first position and a second position, and an actuator configured to operate the lumbar support assembly for movement of the lumbar support member between at least the first position and the second position. When the lumbar support member is in the second position, the lumbar support member is positioned forwardly, in a direction toward the seated user's lower back, relative to the seat back member so as to enable the user to be seated forwardly on the seat pan member while being engaged with the lumbar support member.Type: GrantFiled: June 23, 2021Date of Patent: November 21, 2023Assignee: FELLOWES, INC.Inventors: Tai Hoon K. Matlin, James Waring, Shawn Applegate, Steven James Barnaby, Jr., Peter Maletich, John Fellowes
-
Patent number: 11813560Abstract: An air purifying system includes an air purifier mechanism, a controller, and a sensing device. The sensing device is configured to measure an air quality parameter of the air entering the housing via the air inlet to generate inlet air quality data, and to measure an air quality parameter of the purified air exiting the housing via the air outlet to generate outlet air quality data. The controller is configured to: receive the inlet air quality data and the outlet air quality data, compare the inlet air quality data and the outlet air quality data with their corresponding predetermined threshold ranges, and determine an action to be taken.Type: GrantFiled: December 6, 2017Date of Patent: November 14, 2023Assignee: FELLOWES, INC.Inventors: Peter Maletich, Shawn Michael Applegate, Mitch Rydholm, Steven James Barnaby, Jr., Tai Hoon K. Matlin
-
Publication number: 20230265390Abstract: Several embodiments disclosed herein relate to methods and compositions for enhanced expansion of NK cells in culture. In several embodiments, the methods utilize one or more soluble interleukins as culture media supplements at one or more time points during expansion of the NK cell, or other immune cell, the expansion employing a feeder cell population.Type: ApplicationFiled: August 31, 2021Publication date: August 24, 2023Inventors: James Barnaby Trager, Alexandra Leida Liana Lazetic, Katherine Jamboretz, Muhammad Nafeesur Rahman
-
Publication number: 20230119976Abstract: An air purifier system includes at least one air purifier and a portable user interface device. The user interface device for positioning at a remote location from the at least one air purifier and wirelessly communicated to a controller of at least one of the air purifiers. The user interface device includes a sensor configured to measure an air quality parameter in an area proximate the user interface device for transmission of the air quality parameter to the controller of the at least one of the air purifiers via wireless communication; and a user interface comprising (a) a display for displaying data including at least air quality data from the sensor and (b) a user input control for the user to change one or more functional parameters of the at least one of the air purifiers via the wireless communication.Type: ApplicationFiled: December 21, 2022Publication date: April 20, 2023Applicant: FELLOWES, INC.Inventors: Peter MALETICH, Shawn Michael Applegate, Mitch Rydholm, Steven James Barnaby, JR., Tai Hoon K. Maitlin
-
Publication number: 20230028399Abstract: Provided for herein in several embodiments are immune cell-based compositions comprising BCMA-directed chimeric antigen receptors (CAR). In several embodiments, the immune-cell based compositions also target an additional tumor marker and/or an additional epitope of BCMA. In several embodiments, the BCMA-directed CAR is expressed in a Natural Killer cell. In several embodiments, combinations of BCMA-CAR-expressing NK cells are administered in conjunction with, for example CAR-expressing NK cells and/or CAR-expressing T cells that are directed to an additional cancer marker and/or an additional epitope of BCMA. Also provided for herein are methods and uses of the chimeric antigen receptors in immunotherapy.Type: ApplicationFiled: January 11, 2021Publication date: January 26, 2023Inventors: Kanya Lakshmi Rajangam, James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Alexandra Leida Liana Lazetic
-
Publication number: 20230002471Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.Type: ApplicationFiled: May 10, 2022Publication date: January 5, 2023Inventors: Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
-
Publication number: 20220411754Abstract: Several embodiments disclosed herein relate to methods and compositions for enhanced expansion of NK cells in culture. In several embodiments, the methods utilize one or more soluble interleukins as culture media supplements at one or more time points during expansion of the NK cell, or other immune cell, the expansion employing a feeder cell population.Type: ApplicationFiled: July 29, 2020Publication date: December 29, 2022Inventors: James Barnaby TRAGER, Alexandra Leida Liana LAZETIC, Ivan CHAN, Anmol VOHRA
-
Publication number: 20220233590Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.Type: ApplicationFiled: January 7, 2022Publication date: July 28, 2022Inventors: James Barnaby TRAGER, Luxuan Guo BUREN, Chao GUO, Mira TOHMÉ, Ivan CHAN, Alexandra Leida Liana LAZETIC
-
Publication number: 20220233593Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors and/or genetically modified to enhance one or more aspects of the efficacy of the immune cells in cellular immunotherapy. Several embodiments relate to genetic modifications which reduce potential side effects of cellular immunotherapy. In several embodiments, combinations of cells are used to achieve both rapid and long-term tumor reduction with reduced or eliminated potential for graft versus host effects.Type: ApplicationFiled: June 2, 2020Publication date: July 28, 2022Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Guangnan Li, Daofeng Liu, Ivan Chan
-
Patent number: 11365236Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.Type: GrantFiled: March 27, 2018Date of Patent: June 21, 2022Assignees: NKARTA, INC., NATIONAL UNIVERSITY OF SINGAPOREInventors: Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
-
Patent number: 11253547Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.Type: GrantFiled: November 4, 2020Date of Patent: February 22, 2022Assignee: Nkarta, Inc.Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
-
Publication number: 20220002424Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.Type: ApplicationFiled: June 10, 2021Publication date: January 6, 2022Inventors: James Barnaby Trager, Alexandra Leida Liana Lazetic, Ivan Chan, Chao Guo, Katherine Jamboretz
-
Publication number: 20210338727Abstract: Several embodiments disclosed herein relate to the treatment of a tumor using immunotherapy. Several embodiments relate to the treatment of a liver tumor, such as hepatocellular carcinoma or a metastasis from another tumor location. Additional embodiments relate to combination therapies that employ Natural Killer (NK) cells engineered to express cytotoxic receptor complexes and additional anti-cancer agents to treat tumors.Type: ApplicationFiled: September 11, 2019Publication date: November 4, 2021Inventors: James Barnaby TRAGER, Angela Jean SHEN
-
Patent number: 11154575Abstract: Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.Type: GrantFiled: November 4, 2020Date of Patent: October 26, 2021Assignee: Nkarta, Inc.Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
-
Publication number: 20210321778Abstract: A chair comprises a seat pan member, a seat back member having a lumbar support member, a lumbar support assembly operatively connected to the lumbar support member and configured for moving the lumbar support member, with respect to the seat pan member and the seat back member, between at least a first position and a second position, and an actuator configured to operate the lumbar support assembly for movement of the lumbar support member between at least the first position and the second position. When the lumbar support member is in the second position, the lumbar support member is positioned forwardly, in a direction toward the seated user's lower back, relative to the seat back member so as to enable the user to be seated forwardly on the seat pan member while being engaged with the lumbar support member.Type: ApplicationFiled: June 23, 2021Publication date: October 21, 2021Inventors: Tai Hoon K. Matlin, James Waring, Shawn Applegate, Steven James Barnaby, JR., Peter Maletich, John Fellowes
-
Patent number: 11141436Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.Type: GrantFiled: November 4, 2020Date of Patent: October 12, 2021Assignee: Nkarta, Inc.Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
-
Patent number: 11083299Abstract: A chair includes a seat pan member, a movement support frame, and at least two movement support members operatively connected to the seat pan member and the movement support frame. The at least two movement support members are configured to support the seat pan member in a floating manner for dynamic movement with respect to the movement support frame in at least one degree of freedom in a horizontal seating plane.Type: GrantFiled: February 19, 2020Date of Patent: August 10, 2021Assignee: FELLOWES, INC.Inventors: Tai Hoon K. Matlin, James Waring, Shawn Applegate, Steven James Barnaby, Jr., Peter Maletich, John Fellowes
-
Patent number: 11017143Abstract: The disclosure describes a method for modeling excess base current in irradiated bipolar junction transistors (BJTs). The method includes quantifying defect-related electrostatic effects of a BJT device to help improve accuracy in predicting an irradiated excess base current of the BJT device. The method can be adapted to model the excess base current of a lateral P-type-N-type-P-type (LPNP) BJT device in depleted and/or accumulated surface potential states. The predicted excess base current may be used to qualify or disqualify the BJT device or an electrical circuit including the BJT device for use in a space system(s) as a commercial-off-the-shelf (COTS) component. By modeling the excess base current based on quantifying and utilizing the defect-related electrostatic effects, it may be possible to accurately predict a total-ionizing-dose (TID) response of the BJT device, thus enabling faster and lower-cost qualification of a COTS component(s) for use in the space system(s).Type: GrantFiled: May 25, 2018Date of Patent: May 25, 2021Assignees: Arizona Board of Regents on Behalf of Arizona State University, California Institute of TechnologyInventors: Hugh James Barnaby, Philippe Adell, Blayne Tolleson